Table 2.
Comparison between the survival group and the nonsurvival group at the 28-day, 90-day, and 6-month follow-ups.
| Parameter | 28 days | 90 days | 6 months | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Survivors | Nonsurvivors | P value | Survivors | Nonsurvivors | P value | Survivors | Nonsurvivors | P value | |
| ALT (IU/l) | 26 (18-42) | 25.5 (15.75-56) | 0.512 | 25 (17-38.25) | 27 (16-54.75) | 0.114 | 23 (17-36) | 26 (15-56) | 0.040 |
| AST (IU/l) | 40 (28-68) | 67.5 (38.25-168.25) | <0.001 | 38 (26-57) | 64.5 (36.5-160.25) | <0.001 | 35.5 (26-53) | 58 (36-168) | <0.001 |
| Albumin (g/l) | 28.8 (25.4-31.4) | 25.05 (21.75-28.575) | <0.001 | 29 (25.8-32) | 25.65 (22.8-29.275) | <0.001 | 29.1 (25.925-32.1) | 25.7 (22.8-29.5) | <0.001 |
| Bilirubin (mmol/l) | 23.8 (15.5-39.9) | 36.2 (21.125-73.425) | 0.028 | 22.85 (14.85-38.7) | 27.1 (17.75-58.25) | 0.022 | 21.9 (14.3-37.475) | 29.5 (19.6-57.2) | 0.004 |
| ALP (IU/l) | 70 (53-101) | 115 (68.25-175.5) | <0.001 | 68 (53-96) | 98.5 (67.75-167) | <0.001 | 67 (51.25-92.75) | 95 (67-168) | <0.001 |
| GGT (IU/l) | 23 (14-56) | 38.5 (18-128.75) | 0.020 | 21.5 (13.75-47.25) | 38 (21-106.75) | <0.001 | 21 (13-48) | 37 (17-106) | 0.003 |
| Creatinine (mmol/l) | 72.4 (59.6-91.3) | 92.55 (72.65-134.35) | <0.001 | 72.3 (59.525-88.875) | 92.55 (64.05-135.88) | <0.001 | 71.45 (57.7-86.075) | 91.9 (63.4-132.6) | <0.001 |
| INR | 1.31 (1.2-1.5) | 1.48 (1.24-1.95) | <0.001 | 1.3 (1.18-1.483) | 1.425 (1.27-1.75) | <0.001 | 1.31 (1.19-1.487) | 1.4 (1.24-1.76) | <0.001 |
| PT | 14.7 (13.5-16.7) | 15.1 (13.7-21.45) | 0.002 | 14.65 (13.175-16.425) | 15.6 (13.825-19.9) | <0.001 | 14.7 (13.025-16.4) | 15.4 (13.7-19.9) | <0.001 |
| Platelet (10∗9/l) | 62 (41-96) | 74 (28.25-115.5) | 0.893 | 62 (40.75-92.25) | 69 (32.25-108) | 0.637 | 64 (41-92.75) | 70 (37-109) | 0.419 |
| WBC (10∗9/l) | 6.34 (3.95-9.48) | 9.37 (4.648-14.973) | <0.001 | 6.33 (3.865-9.05) | 8.15 (4.715-13.63) | 0.001 | 6.295 (3.805-9.432) | 7.75 (4.42-13.57) | 0.003 |
| Na (mmol/l) | 138.4 (136-141) | 140.15 (134.45-143.88) | 0.168 | 138.95 (136-141) | 138.45 (134.85-142.75) | 0.939 | 138.6 (136-141.15) | 138.5 (135-142) | 0.967 |
| Child-Pugh score | 8 (7-10) | 10 (8-11) | <0.001 | 8 (7-9) | 9 (8-10.5) | <0.001 | 8 (7-9) | 9.5 (8-11) | <0.001 |
| MELD score | 11 (9-14) | 15 (11-23) | <0.001 | 10.5 (9-14) | 15 (11-20) | <0.001 | 10 (9-14) | 14 (11-19.5) | <0.001 |
| MELD-Na score | 12 (9-15.410) | 16 (12.295-25) | <0.001 | 11 (9-15) | 15 (11.59-23) | <0.001 | 11 (9-14) | 15 (11.59-22.837) | <0.001 |
| iMELD score | 30.695 (27.1-35.578) | 37.14 (30.335-42.35) | <0.001 | 30.3 (26.53-34.1) | 35.9 (29.72-42.2) | <0.001 | 30.17 (26.568-34.265) | 36.1 (29.72-41.9) | <0.001 |
| ALBI score | -1.541 (-1.813~-1.140) | -1.031 (-1.507~-0.449) | <0.001 | -1.548 (-1.851~-1.177) | -1.140 (-1.544~-0.635) | <0.001 | -1.553 (-1.886~-1.228) | -1.152 (-1.562~-0.652) | <0.001 |
Data are expressed as the median (interquartile range). ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; INR: international normalized ratio; PT: prothrombin time; WBC: white blood cell count; MELD: model for end-stage liver disease; MELD-Na: MELD combined with serum sodium concentration; iMELD: integrated MELD; ALBI: albumin-bilirubin score.